Please type a plus sign (+) inside this box → [+]

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/899,552
Filing Date	July 6, 2001
First Named Inventor	Lauraine Wagter-Lesperance
Group Art Unit	1644
Examiner Name	Unknown
Total Number of Pages in This Submission: 9	Attorney Docket Number: 6580-239

RECEIVED
02 DEC 16 AM 11:00
TECH CENTER 1600/2900

RECEIVED
DEC 19 2002
TECH CENTER 1600/2900

ENCLOSURES *(check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment / Response
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☒ Extension of Time Request
- ☐ Express Abandonment Request
- ☐ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☒ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Assignment Papers *(for an Application)*
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s)
- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group *(Appeal Notice, Brief, Reply Brief)*
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) *(please identify below)*:
  - *** Copy of Notice to Comply with Requirements form**
  - *** Sequence Listing in paper form**
  - *** Sequence Listing on diskette**

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	**Patricia Power, Reg. No. 51,379, BERESKIN & PARR**
Signature	P Power
Date	December 13, 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: _____

Typed or printed name			
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/899,552	07/06/2001	Lauraine Wagter-Lesperance	6580-239

CONFIRMATION NO. 7030

FORMALITIES LETTER

OC000000008943902

Micheline Gravelle
Bereskin & Parr
40 King Street West
Box 401
Toronto, ON M5H 3Y2
CANADA

Date Mailed: 10/11/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- **For Rules Interpretation, call (703) 308-4216**
- **To Purchase PatentIn Software, call (703) 306-2600**
- **For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov**

A copy of this notice MUST be returned with the reply.

N/A

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

ATTACHMENT TO "NOTICE TO COMPLY WITH REQUIREMENTS...SEQUENCE DISCLOSURES"

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be submitted using one of the following methods:

1. Electronically submitted through EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual - ePAVE)

2. Mailed to:
   U.S. Patent and Trademark Office
   Box Sequence, P.O. Box 2327
   Arlington, VA 22202

3. Mailed by Federal Express, United Parcel Service or other delivery service to:
   U. S. Patent and Trademark Office
   2011 South Clark Place
   Customer Window, Box Sequence
   Crystal Plaza Two, Lobby, Room 1B03
   Arlington, Virginia 22202

4. Hand Carried directly to the Customer Window at:
   2011 South Clark Place
   Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,
   Arlington, Virginia 22202

9. The method according to claim 8, wherein the bovine is selected from a multiparous cow and a primiparous cow.

10. The method according to claim 8, wherein the bovine is a multiparous cow.

11. The method according to claim 1, wherein the antigen is selected from the group consisting of hen egg white lysozyme, human serum albumin, tyrosine-glycine-alanine-lysine copolymer and ovalbumin.

12. The method according to claim 11, wherein the antigen is ovalbumin.

13. The method according to claim 12, wherein the antigen is formualted with an adjuvant selected from the group consisting of Freunds complete adjuvant (FCA), non-ulcerative Freunds adjuvant (NUFA), complete NUFA and *mycobacteria* cell wall extract.

14. The method according to claim 1, wherein the antigen is formulated into a vaccine.

15. The method according to claim 14, wherein the vaccine is *Escherichia coli* J5.

16. The method according to claim 1, wherein a source for measuring the antibody response is selected from the group consisting of blood and milk.

17. The method according to claim 7, wherein the measuring of the antibody response at least once before the onset of the stress is at about 8

Sequence
Tyrosine - Glycine - Alanine - Lysine